Literature DB >> 11025778

The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP.

F S Leach1, A Velasco, J T Hsieh, A I Sagalowsky, J D McConnell.   

Abstract

PURPOSE: Mismatch repair genes are responsible for the coordinated correction of misincorporated nucleotides formed during DNA replication. Inactivating and inherited mutations in the prototypic mismatch repair gene hMSH2 have been described in a cancer predisposition syndrome known as hereditary nonpolyposis colon cancer. Patients with hereditary nonpolyposis colon cancer are at increased risk for colon cancer and extracolonic cancers such as upper tract transitional cell carcinoma but not prostate cancer. We investigated expression of hMSH2 in prostate cancer cell lines using genetic and molecular analysis.
MATERIALS AND METHODS: We used the 3 well described prostate cancer cell lines, DU145, LNCaP and PC3. Western blot analysis with monoclonal antibody to hMSH2 was used to assess expression. Southern blot and polymerase chain reaction of genomic DNA were used to identify genetic alterations in the hMSH2 gene. Single cell cloning, dinucleotide repeats and BAT-26 were used to assess the cell lines for microsatellite instability.
RESULTS: The prostate cancer cell line LNCaP did not express hMSH2 and was found to have a homozygous deletion of hMSH2 exons 9 to 16, resulting in truncation of the protein. While microsatellite analysis did not reveal alterations at the BAT-26 locus, single cell cloning produced several LNCaP subclones with alteration at 1 dinucleotide repeat.
CONCLUSIONS: The well described prostate cancer cell line LNCaP has a mutation in the hMSH2 gene, resulting in loss of expression and possible evidence of microsatellite instability. To our knowledge our finding is the first demonstration of a genetic alteration in hMSH2 in a prostate cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025778

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants.

Authors:  A Brieger; J Trojan; J Raedle; G Plotz; S Zeuzem
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

2.  Resistance emerges to second-generation antiandrogens in prostate cancer.

Authors:  William G Nelson; Srinivasan Yegnasubramanian
Journal:  Cancer Discov       Date:  2013-09       Impact factor: 39.397

3.  MSH2 Loss in Primary Prostate Cancer.

Authors:  Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan
Journal:  Clin Cancer Res       Date:  2017-08-08       Impact factor: 12.531

4.  Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Authors:  Wendy J Langeberg; Erika M Kwon; Joseph S Koopmeiners; Elaine A Ostrander; Janet L Stanford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01       Impact factor: 4.254

5.  Mismatch repair enzyme expression in primary and castrate resistant prostate cancer.

Authors:  Belinda Nghiem; Xiaotun Zhang; Hung-Ming Lam; Lawrence D True; Ilsa Coleman; Celestia S Higano; Peter S Nelson; Colin C Pritchard; Colm Morrissey
Journal:  Asian J Urol       Date:  2016-09-12

6.  A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer.

Authors:  Inês Teles Alves; David Cano; René Böttcher; Hetty van der Korput; Winand Dinjens; Guido Jenster; Jan Trapman
Journal:  Oncotarget       Date:  2017-01-24

Review 7.  Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer.

Authors:  Kristine M Wadosky; Shahriar Koochekpour
Journal:  Oncotarget       Date:  2016-09-27

Review 8.  The genomic landscape of prostate cancer.

Authors:  Lien Spans; Liesbeth Clinckemalie; Christine Helsen; Dirk Vanderschueren; Steven Boonen; Evelyne Lerut; Steven Joniau; Frank Claessens
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

9.  Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.

Authors:  Lien Spans; Christine Helsen; Liesbeth Clinckemalie; Thomas Van den Broeck; Stefan Prekovic; Steven Joniau; Evelyne Lerut; Frank Claessens
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

10.  Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.

Authors:  Yezi Zhu; Susan L Dalrymple; Ilsa Coleman; S Lilly Zheng; Jianfeng Xu; Jody E Hooper; Emmanuel S Antonarakis; Angelo M De Marzo; Alan K Meeker; Peter S Nelson; William B Isaacs; Samuel R Denmeade; Jun Luo; W Nathaniel Brennen; John T Isaacs
Journal:  Oncogene       Date:  2020-09-28       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.